One of two biologics injected intravitreally to treat forms of macular degeneration, edema, or retinopathy, Eylea® (aflibercept) was first approved by the US Food and Drug Administration (FDA) on November 18, 2011. Originally approved as a single-dose vial, its manufacturer, Regeneron, received FDA approval of a prefilled syringe in December 2019. We covered the potential … Continue reading Who Are the Key Aflibercept Biosimilar Players to Watch?
Tag: ALT-L9
A Profile on Lesser-Known Player in the Biosimilar Space: Alteogen Inc
On occasion, we profile some biosimilar manufacturers about whom our readers may not be familiar. This generally refers to companies that have products that are in earlier-stage research or those who simply have not been in the news as often as their colleagues. In this post, we highlight a South Korean-based company, Alteogen Inc. Established … Continue reading A Profile on Lesser-Known Player in the Biosimilar Space: Alteogen Inc